FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead
STERIS Corporation, a wholly owned operating subsidiary of STERIS plc, agreed to buy Xodus Medical, Inc. for $2.1 billion in cash on October 12, 2026, according to a corporate press release...
Viatris Inc. agreed to purchase Pacira BioSciences Inc. for $36.50 per share in cash on October 8, 2026, establishing an equity valuation of approximately $1.65 billion. The transaction establishes...
Shionogi & Co., Ltd. agreed to acquire IntraBio Inc. for $2.0 billion in an all-cash transaction announced on October 5, 2026. The Japanese pharmaceutical company will purchase 100 percent of the...
GE HealthCare announced on October 5, 2026, that it agreed to purchase SOFIE Biosciences from private equity firm Trilantic North America for $945 million in cash. SOFIE Biosciences operates as a...
